Yuan Xianwen, Chen Jun, Cheng Qi, Zhao Yinjuan, Zhang Pengzi, Shao Xiaoyan, Bi Yan, Shi Xiaolei, Ding Yitao, Sun Xitai, Xue Bin
State Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Key Laboratory of Molecular Medicine and School of Medicine, Nanjing University, Nanjing, Jiangsu Province, China.
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China.
BMC Gastroenterol. 2018 Oct 3;18(1):147. doi: 10.1186/s12876-018-0871-2.
This study is to investigate the association between the hepatic expression of Yin Yang 1 (YY1) and the progression of non-alcoholic fatty liver disease (NAFLD) in patients undergoing bariatric surgery.
Obese patients undergoing bariatric surgery were included. Liver tissues were subjected to the quantitative real-time PCR, Western blot analysis, and immunohistochemical assay, to determine the expression levels of YY1.
Totally 88 patients were included. According to the NAFLD activity score (NAS), these patients were divided into the control (n = 12), steatosis (n = 20), non-defining NASH (n = 38), and NASH (n = 18) groups. Significant differences in the serum glucose, insulin, ALT, AST, and HOMA-IR levels were observed among these different NAFLD groups. Hepatic YY1 expression had correlation with serum glucose, insulin, HOMA-IR, ALT, AST, triglycerides, HDL, and GGT. Immunohistochemical analysis showed that, compared with the control group, the expression levels of YY1 were significantly higher in the non-defining NASH and NASH groups. In addition, multivariate regression model showed that the serum ALT and YY1 levels were strongly associated with the NAFLD activity.
Several factors are associated with NAFLD progression, including the expression of YY1. Our findings contribute to understanding of the pathogenesis of NAFLD.
NCT03296605 , registered on September 28, 2017.
本研究旨在调查接受减肥手术患者的阴阳1（YY1）肝脏表达与非酒精性脂肪性肝病（NAFLD）进展之间的关联。
纳入接受减肥手术的肥胖患者。对肝组织进行定量实时聚合酶链反应、蛋白质免疫印迹分析和免疫组织化学检测，以确定YY1的表达水平。
共纳入88例患者。根据NAFLD活动评分（NAS），这些患者被分为对照组（n = 12）、脂肪变性组（n = 20）、未明确的非酒精性脂肪性肝炎组（n = 38）和非酒精性脂肪性肝炎组（n = 18）。在这些不同的NAFLD组中，观察到血清葡萄糖、胰岛素、谷丙转氨酶、谷草转氨酶和稳态模型评估的胰岛素抵抗（HOMA-IR）水平存在显著差异。肝脏YY1表达与血清葡萄糖、胰岛素、HOMA-IR、谷丙转氨酶、谷草转氨酶、甘油三酯、高密度脂蛋白和γ-谷氨酰转移酶相关。免疫组织化学分析显示，与对照组相比，未明确的非酒精性脂肪性肝炎组和非酒精性脂肪性肝炎组中YY1的表达水平显著更高。此外，多变量回归模型显示，血清谷丙转氨酶和YY1水平与NAFLD活动密切相关。
几个因素与NAFLD进展相关，包括YY1的表达。我们的研究结果有助于理解NAFLD的发病机制。
NCT03296605，于2017年9月28日注册。
